Comparative Pharmacology
Head-to-head clinical analysis: BIORPHEN versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIORPHEN versus VIGPODER.
BIORPHEN vs VIGPODER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Treatment of hypotension during anesthesiaTreatment of mild to moderate hypotensionVasopressor support in shock states (off-label)Management of paroxysmal supraventricular tachycardia (off-label)
Monotherapy for infantile spasms (West syndrome) in children 1 month to 2 years of ageAdjuvant therapy for refractory complex partial seizures in adults
Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.
150 mg orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours (short-acting opioid; context: requires q4h dosing for sustained analgesia).
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Primarily hepatic metabolism by monoamine oxidase (MAO) and sulfotransferase; minor renal excretion.
Vigabatrin is not significantly metabolized; it is eliminated primarily unchanged by renal excretion via glomerular filtration. No hepatic metabolism via CYP450 enzymes.
Renal: 90% as glucuronide conjugates; Fecal: 10% (unabsorbed/biliary).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
~35% bound to albumin.
98% bound to albumin and alpha-1-acid glycoprotein.
Vd: 3–5 L/kg (large distribution indicates extensive tissue uptake, e.g., brain, fat).
0.8 L/kg (total body water); indicates extensive tissue distribution.
Oral: 50–60% (first-pass); Rectal: ~50%; IM/IV: 100%.
Oral: 85% (range 75–95%); IV: 100%.
GFR 10-50 mL/min: administer 75% of usual dose every 6 hours; GFR <10 mL/min: administer 50% of usual dose every 6 hours.
GFR 30-59 mL/min: 150 mg once daily. GFR 15-29 mL/min: 150 mg every other day. GFR <15 mL/min (not on dialysis): not recommended. Hemodialysis: administer after dialysis on dialysis days.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% or avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce to 150 mg once daily. Child-Pugh C: not recommended.
Children: 0.1-0.2 mg/kg IV/IM/SC every 2-4 hours as needed; oral: 0.3-0.5 mg/kg every 4-6 hours as needed. Maximum single dose: 15 mg.
Weight <30 kg: 5 mg/kg orally twice daily; maximum 150 mg/dose. Weight ≥30 kg: same as adult dosing.
Initiate at 50% of adult dose with cautious titration; monitor for CNS depression and constipation.
No specific dose adjustment; consider renal function and potential for age-related decline in GFR. Monitor for dizziness and falls.
No FDA boxed warning.
Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision, and may result in permanent vision loss. Risk increases with cumulative dose and duration of therapy. Vision assessment is required before and during treatment.
["May cause severe hypertension and bradycardia","Use with caution in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis","Risk of extravasation with local tissue necrosis","Monitor blood pressure continuously during administration","May exacerbate angle-closure glaucoma"]
["Visual field defects and vision loss require baseline and periodic vision monitoring","Magnetic resonance imaging (MRI) abnormalities: intramyelinic edema in infants may resolve after discontinuation","Suicidal thoughts and behavior: monitor for neuropsychiatric symptoms","Abrupt discontinuation may precipitate withdrawal seizures; taper gradually","Renal impairment requires dose adjustment","May cause somnolence and dizziness; avoid driving or hazardous activities"]
["Hypersensitivity to phenylephrine or any component","Severe hypertension","Ventricular tachycardia","Patients receiving monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOI therapy"]
["Hypersensitivity to vigabatrin or any component of the formulation","Pre-existing visual field defects or significant vision loss (unless benefits outweigh risks)"]
Data Pending Review
Data Pending Review
No food interactions known; BIORPHEN is topical and not systemically absorbed.
Take with food to reduce gastrointestinal upset. Avoid high-fat meals as they may increase absorption and risk of side effects. No known significant food-drug interactions with VIGPODER specifically; however, alcohol may potentiate CNS depression.
BIORPHEN is contraindicated in pregnancy. First trimester: risk of fetal malformations including neural tube defects and cleft palate. Second and third trimesters: risk of neonatal withdrawal, respiratory depression, and sedation due to placental transfer and fetal accumulation. Use only if clearly needed and no safer alternative exists.
VIGPODER is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth retardation, neurodevelopmental impairment, and potential for neonatal withdrawal syndrome. There is no safe trimester for use.
BIORPHEN is excreted in human breast milk with an M/P ratio of approximately 0.7. It may cause respiratory depression and sedation in the breastfed infant. Because of the potential for serious adverse reactions, advise patients to avoid breastfeeding while using BIORPHEN.
VIGPODER is excreted in human breast milk; the milk-to-plasma ratio is approximately 0.8. Due to potential for serious adverse reactions in nursing infants, including sedation and respiratory depression, breastfeeding is contraindicated during therapy and for 5 days after the last dose.
No specific dose adjustments in pregnancy; however, use lowest effective dose for shortest duration due to altered pharmacokinetics (increased clearance) in later pregnancy. Taper dose gradually to avoid maternal withdrawal.
No dose adjustment is recommended in pregnancy because VIGPODER is contraindicated. However, if used in a life-threatening situation without alternatives, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may necessitate a 20-30% dose increase to maintain therapeutic levels, with close monitoring of drug concentrations and clinical response.
Category C
Category C
BIORPHEN (bioresmethrin) is a pyrethroid insecticide used topically for pediculosis. Avoid contact with eyes and mucous membranes. Do not use on open wounds or broken skin. Reapply after 7-10 days if live lice persist. Resistance is rare but monitor efficacy.
VIGPODER is a prodrug of vigabatrin, indicated for treatment-resistant complex partial seizures and infantile spasms. Monitor for irreversible vision loss (bilateral concentric visual field defects) with baseline and periodic ophthalmologic exams. Start at low doses and titrate slowly to minimize CNS depression. Discontinue gradually to avoid withdrawal seizures. Contraindicated in pregnancy (teratogenic) and severe hepatic impairment.
Apply only to dry hair and scalp, avoiding eyes.Leave on for 10 minutes, then rinse thoroughly.Use a fine-toothed comb to remove nits.Do not use more than once daily or exceed recommended duration.Wash bedding and clothing in hot water.Inform doctor if itching or irritation persists.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.Report any vision changes (blurring, loss of peripheral vision) immediately.Avoid driving or operating machinery until you know how this drug affects you.This drug can cause dizziness, drowsiness, or confusion; avoid alcohol.Use effective contraception if you are of childbearing age; discuss with your doctor if pregnant or planning pregnancy.Do not change dose or frequency without medical advice.